Novo Nordisk and Flagship Pioneering partner to create a portfolio of transformational medicines

Pioneering Medicines and Novo Nordisk Bio Innovation Hub will leverage Flagship Pioneering’s bioplatform companies to create a portfolio of research programmes within cardiometabolic and rare diseases

Novo Nordisk expands research collaboration for biologic medicines

This collaboration has resulted in several high-impact scientific publications describing breakthrough inventions, including the SOMA robotic pill, which has subsequently been licensed exclusively to Novo Nordisk for clinical development

Novo Nordisk India launches world’s first and only GLP-1 RA, oral semaglutide

Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach

Novo Nordisk to acquire Dicerna Pharmaceuticals for US $ 3.3 bn

Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease

EMA backs higher-dose Wegovy, clearing path for greater weight loss option in Europe

Trump clinches historic deal as Lilly, Novo slash U.S. weight-loss drug prices

Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans

Nitinotes secures CE mark for automated suturing platform ‘EndoZip’

Enabling a new era in minimally invasive obesity treatment across Europe

FDA rejects Regeneron’s Eylea HD pre-filled syringe application amid manufacturing setbacks

Lupin launches Liraglutide injection in US

Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen is bioequivalent to Victoza Injection, 18 mg/3 mL (6 mg/mL) of Novo Nordisk

Lupin receives USFDA approvals for Liraglutide and Glucagon injectable products

Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India